Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China

• Main Authors: Zhaojun Mo (Author), Yi Nong (Author), Shuzhen Liu (Author), Ming Shao (Author), Xueyan Liao (Author), Kerry Go (Author), Nathalie Lavis (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A split-virion trivalent inactivated influenza vaccine produced according to the Chinese pharmacopeia (Shz-IIV3) has been commercially available in China since 2014. Here, we describe the results of a phase IV open-label trial to describe the immunogenicity and safety of the 2014-2015 Northern Hemis...